Details of the Drug Combination

General Information of Drug Combination (ID: DC5CGEG)

Drug Combination Name
Propranolol Fenofibrate
Indication
Disease Entry Status REF
Burn Phase 2 [1]
Component Drugs Propranolol   DM79NTF Fenofibrate   DMFKXDY
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Propranolol
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Approved [2]
Atrial fibrillation BC81.3 Approved [2]
Cocaine addiction 6C45.2 Approved [2]
Hemangioma 2E81-2F2Y Approved [2]
Migraine 8A80 Approved [3]
Respiratory papillomatosis 2F00.1 Investigative [2]
Propranolol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Antagonist [7]
------------------------------------------------------------------------------------
Propranolol Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [9]
Organic cation transporter 3 (SLC22A3) DT6201N S22A3_HUMAN Substrate [9]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Propranolol Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [10]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [11]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [13]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [13]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [14]
Dimethylaniline oxidase 2 (FMO2) DEIASEZ FMO2_HUMAN Metabolism [15]
Cytochrome P450 102A1 (cyp102) DE4OGUF CPXB_BACMB Metabolism [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Propranolol Interacts with 34 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Oxidation [17]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Oxidation [17]
Flavin-containing monooxygenase 2 (FMO2) OTUJUL9S FMO2_HUMAN Increases Oxidation [15]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [18]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [19]
Potassium voltage-gated channel subfamily KQT member 1 (KCNQ1) OT8SPJNX KCNQ1_HUMAN Affects Response To Substance [20]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Decreases Expression [6]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Expression [6]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [6]
Angiopoietin-2 (ANGPT2) OTEQK65P ANGP2_HUMAN Decreases Expression [21]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [22]
Renin (REN) OT52GZR2 RENI_HUMAN Decreases Activity [23]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Decreases Expression [24]
Insulin (INS) OTZ85PDU INS_HUMAN Decreases Expression [25]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Decreases Expression [26]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [21]
Ornithine decarboxylase (ODC1) OTNDAGRR DCOR_HUMAN Increases Activity [27]
Beta-adrenergic receptor kinase 1 (GRK2) OT34KKWK ARBK1_HUMAN Decreases Expression [28]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [29]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [30]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [21]
Neurogenic locus notch homolog protein 1 (NOTCH1) OTI1WADQ NOTC1_HUMAN Decreases Expression [29]
G protein-activated inward rectifier potassium channel 1 (KCNJ3) OTHQG16J KCNJ3_HUMAN Increases Expression [26]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [30]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Cleavage [31]
ADP-ribosylation factor 6 (ARF6) OTVV7KJO ARF6_HUMAN Affects Localization [32]
Angiopoietin-1 receptor (TEK) OT78YN57 TIE2_HUMAN Decreases Expression [21]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [21]
Delta-like protein 4 (DLL4) OTRA4K2V DLL4_HUMAN Decreases Expression [29]
Inward rectifier potassium channel 2 (KCNJ2) OT2OQEZS KCNJ2_HUMAN Affects Response To Substance [20]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases ADR [33]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Increases Oxidation [17]
Sodium channel protein type 5 subunit alpha (SCN5A) OTGYZWR6 SCN5A_HUMAN Increases ADR [33]
Potassium voltage-gated channel subfamily E member 1 (KCNE1) OTZNQUW9 KCNE1_HUMAN Increases ADR [33]
------------------------------------------------------------------------------------
⏷ Show the Full List of 34 DOT(s)
Indication(s) of Fenofibrate
Disease Entry ICD 11 Status REF
Coronary atherosclerosis N.A. Approved [4]
High cholesterol level 5C80.0 Approved [5]
Hypercholesterolaemia 5C80.0 Approved [4]
Hyperlipidemia 5C80.Z Approved [4]
Hyperlipidemia, familial combined, LPL related N.A. Approved [4]
Hypertriglyceridemia 5C80.1 Approved [4]
Obesity 5B81 Approved [4]
Fenofibrate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Peroxisome proliferator-activated receptor alpha (PPARA) TTJ584C PPARA_HUMAN Agonist [38]
------------------------------------------------------------------------------------
Fenofibrate Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [39]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [40]
------------------------------------------------------------------------------------
Fenofibrate Interacts with 240 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [41]
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Increases Expression [41]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [42]
S-adenosylmethionine synthase isoform type-2 (MAT2A) OTFJMIQR METK2_HUMAN Decreases Expression [42]
Phosphoenolpyruvate carboxykinase , mitochondrial (PCK2) OTJ8LX4N PCKGM_HUMAN Increases Expression [42]
Acyl-CoA (FADS1) OTUYOYHX FADS1_HUMAN Increases Expression [43]
Aldo-keto reductase family 1 member B10 (AKR1B10) OTOA4HTH AK1BA_HUMAN Decreases Activity [44]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Increases Expression [45]
Cytochrome P450 3A7 (CYP3A7) OTTCDHHM CP3A7_HUMAN Increases Expression [45]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Increases Activity [46]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [47]
Isocitrate dehydrogenase subunit beta, mitochondrial (IDH3B) OTR89YF5 IDH3B_HUMAN Increases Expression [35]
Apolipoprotein C-III (APOC3) OTW3520C APOC3_HUMAN Decreases Expression [35]
Lipoprotein lipase (LPL) OTTW0267 LIPL_HUMAN Increases Expression [35]
Fatty acid-binding protein, liver (FABP1) OTR34ETM FABPL_HUMAN Increases Expression [35]
3-ketoacyl-CoA thiolase, peroxisomal (ACAA1) OTVKRET0 THIK_HUMAN Increases Expression [35]
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADM) OTA4P0FC ACADM_HUMAN Increases Expression [35]
Succinate dehydrogenase iron-sulfur subunit, mitochondrial (SDHB) OTRE1M1T SDHB_HUMAN Increases Expression [35]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1) OTJC60Q7 THIL_HUMAN Increases Expression [35]
Enoyl-CoA hydratase, mitochondrial (ECHS1) OTS0593S ECHM_HUMAN Increases Expression [35]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Increases Expression [35]
Phosphoglucomutase-1 (PGM1) OT3VM4JX PGM1_HUMAN Increases Expression [35]
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADVL) OT50L4XB ACADV_HUMAN Increases Expression [35]
Succinate--CoA ligase subunit alpha, mitochondrial (SUCLG1) OTDCSPXH SUCA_HUMAN Increases Expression [35]
Trifunctional enzyme subunit beta, mitochondrial (HADHB) OT4Y1I62 ECHB_HUMAN Increases Expression [35]
Methylmalonate-semialdehyde/malonate-semialdehyde dehydrogenase , mitochondrial (ALDH6A1) OT8LCZCT MMSA_HUMAN Increases Expression [35]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Decreases Expression [35]
Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) OTM0A0DY ACOX1_HUMAN Increases Expression [35]
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial (HADH) OTJDOL20 HCDH_HUMAN Increases Expression [35]
Long-chain fatty acid transport protein 4 (SLC27A4) OTWT4HAF S27A4_HUMAN Increases Expression [35]
Aconitate hydratase, mitochondrial (ACO2) OTF2UVNV ACON_HUMAN Increases Expression [35]
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) OTQ4W7MT TR11B_HUMAN Decreases Expression [36]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Decreases Expression [36]
Krueppel-like factor 11 (KLF11) OTKVQDJD KLF11_HUMAN Increases Expression [36]
Long-chain fatty acid transport protein 2 (SLC27A2) OT7JEG5F S27A2_HUMAN Increases Expression [36]
Transcription intermediary factor 1-alpha (TRIM24) OTA45FTS TIF1A_HUMAN Increases Expression [36]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Decreases Expression [36]
Interleukin-1 receptor-associated kinase-like 2 (IRAK2) OT6Y1QZN IRAK2_HUMAN Increases Expression [36]
Proline dehydrogenase 1, mitochondrial (PRODH) OT7SQ1C7 PROD_HUMAN Decreases Expression [36]
Aquaporin-9 (AQP9) OTLGH5ZY AQP9_HUMAN Decreases Expression [36]
LYR motif-containing protein 1 (LYRM1) OTV3AJDJ LYRM1_HUMAN Increases Expression [36]
Mitochondrial carnitine/acylcarnitine carrier protein (SLC25A20) OT6CLFXB MCAT_HUMAN Increases Expression [36]
Perilipin-1 (PLIN1) OT3OAAZ4 PLIN1_HUMAN Increases Expression [36]
Peroxisomal membrane protein 11A (PEX11A) OT8MJ9CJ PX11A_HUMAN Increases Expression [36]
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21) OT3EDGXO TNR21_HUMAN Increases Expression [36]
2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial (GCAT) OT6WZPWV KBL_HUMAN Decreases Expression [36]
Alcohol dehydrogenase 1C (ADH1C) OTO1DV7F ADH1G_HUMAN Decreases Expression [36]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL) OTG7J4BP PPBT_HUMAN Decreases Expression [36]
L-lactate dehydrogenase B chain (LDHB) OT9B1CT3 LDHB_HUMAN Increases Expression [36]
Galactose-1-phosphate uridylyltransferase (GALT) OTCATU66 GALT_HUMAN Increases Expression [36]
All-trans-retinol dehydrogenase ADH4 (ADH4) OTKDKKNG ADH4_HUMAN Decreases Expression [36]
Monocyte differentiation antigen CD14 (CD14) OT83GJ47 CD14_HUMAN Increases Expression [36]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Increases Expression [36]
Electron transfer flavoprotein subunit alpha, mitochondrial (ETFA) OTXX61VZ ETFA_HUMAN Increases Expression [36]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Increases Expression [36]
Platelet glycoprotein 4 (CD36) OT5CZWKY CD36_HUMAN Increases Expression [36]
Fumarylacetoacetase (FAH) OTGZA1YR FAAA_HUMAN Increases Expression [36]
Arylacetamide deacetylase (AADAC) OT8VACT2 AAAD_HUMAN Increases Expression [36]
Plasma membrane calcium-transporting ATPase 4 (ATP2B4) OTMWFDAC AT2B4_HUMAN Increases Expression [36]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Increases Expression [36]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1) OTO7FJA9 DHI1_HUMAN Increases Expression [36]
Pyruvate kinase PKLR (PKLR) OTTTM1QI KPYR_HUMAN Decreases Expression [36]
Glycerol kinase (GK) OTK2YRA0 GLPK_HUMAN Increases Expression [36]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Expression [36]
Phosphoenolpyruvate carboxykinase, cytosolic (PCK1) OTNWEJ5Y PCKGC_HUMAN Increases Expression [36]
Glucose-6-phosphatase catalytic subunit 1 (G6PC1) OTJ6FM9F G6PC1_HUMAN Decreases Expression [36]
Trifunctional enzyme subunit alpha, mitochondrial (HADHA) OTO557N2 ECHA_HUMAN Increases Expression [36]
3-ketoacyl-CoA thiolase, mitochondrial (ACAA2) OTGLVWOP THIM_HUMAN Increases Expression [36]
Tryptophan 2,3-dioxygenase (TDO2) OTV5HKJ4 T23O_HUMAN Increases Expression [36]
Flavin-containing monooxygenase 5 (FMO5) OTTILF8T FMO5_HUMAN Decreases Expression [36]
Peroxisomal multifunctional enzyme type 2 (HSD17B4) OT8733D7 DHB4_HUMAN Increases Expression [36]
Hydroxymethylglutaryl-CoA synthase, mitochondrial (HMGCS2) OTC3RUN9 HMCS2_HUMAN Increases Expression [36]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Increases Expression [36]
Tyrosine-protein kinase Mer (MERTK) OTWBRAJ6 MERTK_HUMAN Increases Expression [36]
Krueppel-like factor 10 (KLF10) OT4F4UGS KLF10_HUMAN Increases Expression [36]
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) OTTUU92F ENPP2_HUMAN Decreases Expression [36]
Glycine N-methyltransferase (GNMT) OT0O2OQO GNMT_HUMAN Decreases Expression [36]
Metabotropic glutamate receptor 3 (GRM3) OTJFGE9S GRM3_HUMAN Increases Expression [36]
Hepatic sodium/bile acid cotransporter (SLC10A1) OTUJVMCL NTCP_HUMAN Decreases Expression [36]
Monocyte to macrophage differentiation factor (MMD) OTB5I4OC PAQRB_HUMAN Increases Expression [36]
2'-5'-oligoadenylate synthase-like protein (OASL) OTZ05YRP OASL_HUMAN Increases Expression [36]
Myosin light chain kinase, smooth muscle (MYLK) OT78QB4A MYLK_HUMAN Decreases Expression [36]
Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (ETFDH) OTOSKSFH ETFD_HUMAN Increases Expression [36]
Laminin subunit alpha-4 (LAMA4) OTHI7TA0 LAMA4_HUMAN Increases Expression [36]
kinase isozyme 4, mitochondrial (PDK4) OTCMHMBZ PDK4_HUMAN Increases Expression [36]
Phospholipase A1 member A (PLA1A) OT2IXYNX PLA1A_HUMAN Increases Expression [36]
Protein LBH (LBH) OT87AT1X LBH_HUMAN Increases Expression [36]
NEDD4-binding protein 2-like 1 (N4BP2L1) OTEGV3GO N42L1_HUMAN Increases Expression [36]
Cytochrome P450 4A22 (CYP4A22) OTHO7KC4 CP4AM_HUMAN Increases Expression [36]
Protein FAM222A (FAM222A) OTRD9AUH F222A_HUMAN Increases Expression [36]
PI-PLC X domain-containing protein 3 (PLCXD3) OTJNSWMU PLCX3_HUMAN Decreases Expression [36]
Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3) OTDMU3GP CR3L3_HUMAN Increases Expression [36]
Lysophospholipid acyltransferase 5 (LPCAT3) OTWI96P4 MBOA5_HUMAN Increases Expression [36]
Solute carrier family 25 member 34 (SLC25A34) OTY1YFLG S2534_HUMAN Increases Expression [36]
Leucine-rich repeat-containing protein 31 (LRRC31) OT7VCU13 LRC31_HUMAN Increases Expression [36]
Lysophosphatidylcholine acyltransferase 2 (LPCAT2) OT6NTBAA PCAT2_HUMAN Increases Expression [36]
Monocarboxylate transporter 13 (SLC16A13) OTAJ5CPB MOT13_HUMAN Increases Expression [36]
Target of Nesh-SH3 (ABI3BP) OTW8DN50 TARSH_HUMAN Decreases Expression [36]
Alpha-protein kinase 2 (ALPK2) OTWZZDQ9 ALPK2_HUMAN Increases Expression [36]
4-hydroxy-2-oxoglutarate aldolase, mitochondrial (HOGA1) OT7XETW4 HOGA1_HUMAN Decreases Expression [36]
Sphingosine-1-phosphate transporter SPNS2 (SPNS2) OTPODAPU SPNS2_HUMAN Increases Expression [36]
Cyclin-dependent kinase 20 (CDK20) OTOLNN68 CDK20_HUMAN Increases Expression [36]
Cytochrome P450 4X1 (CYP4X1) OTMTEUNE CP4X1_HUMAN Increases Expression [36]
Uncharacterized protein FAM241A (FAM241A) OTC12ETA F241A_HUMAN Increases Expression [36]
Sodium-dependent lysophosphatidylcholine symporter 1 (MFSD2A) OTVG1VG0 NLS1_HUMAN Decreases Expression [36]
Pantothenate kinase 1 (PANK1) OT2CZVRT PANK1_HUMAN Increases Expression [36]
Thyroid hormone-inducible hepatic protein (THRSP) OTKYE01L THRSP_HUMAN Decreases Expression [36]
Interferon regulatory factor 7 (IRF7) OTC1A2PQ IRF7_HUMAN Increases Expression [36]
Bcl-2-modifying factor (BMF) OT90NSLI BMF_HUMAN Increases Expression [36]
Membrane-spanning 4-domains subfamily A member 10 (MS4A10) OTH3LAUX M4A10_HUMAN Decreases Expression [36]
Perilipin-2 (PLIN2) OTRXJ9UN PLIN2_HUMAN Increases Expression [36]
C-C motif chemokine 13 (CCL13) OTNX0JD0 CCL13_HUMAN Increases Expression [36]
Ion channel TACAN (TMEM120A) OTBS3YWY TACAN_HUMAN Decreases Expression [36]
Angiopoietin-related protein 4 (ANGPTL4) OTQL5SPX ANGL4_HUMAN Increases Expression [36]
Alanine--glyoxylate aminotransferase 2, mitochondrial (AGXT2) OTO6QUTM AGT2_HUMAN Decreases Expression [36]
cAMP-dependent protein kinase inhibitor beta (PKIB) OT7C8GFN IPKB_HUMAN Increases Expression [36]
Potassium channel subfamily K member 13 (KCNK13) OTMOT2KX KCNKD_HUMAN Increases Expression [36]
Serine/threonine-protein kinase Sgk2 (SGK2) OTCTVSHF SGK2_HUMAN Increases Expression [36]
Acetyl-coenzyme A synthetase, cytoplasmic (ACSS2) OTB1FZJU ACSA_HUMAN Decreases Expression [36]
Protein C19orf12 (C19ORF12) OTVSJ1AR CS012_HUMAN Increases Expression [36]
Ethanolamine kinase 2 (ETNK2) OT5S1Z75 EKI2_HUMAN Decreases Expression [36]
Phosphatidylethanolamine N-methyltransferase (PEMT) OTKXRUL9 PEMT_HUMAN Increases Expression [36]
SH3 domain-binding glutamic acid-rich-like protein 2 (SH3BGRL2) OTOX4XT7 SH3L2_HUMAN Increases Expression [36]
Excitatory amino acid transporter 5 (SLC1A7) OTVN5C6W EAA5_HUMAN Increases Expression [37]
Podocalyxin (PODXL) OTPNQXF3 PODXL_HUMAN Decreases Expression [37]
Class E basic helix-loop-helix protein 40 (BHLHE40) OTITX14U BHE40_HUMAN Decreases Expression [37]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [37]
Branched-chain-amino-acid aminotransferase, mitochondrial (BCAT2) OT8L6EGI BCAT2_HUMAN Increases Expression [37]
Transcription factor MafG (MAFG) OTBQFUZH MAFG_HUMAN Increases Expression [37]
D-3-phosphoglycerate dehydrogenase (PHGDH) OT1LMRTG SERA_HUMAN Increases Expression [37]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1) OTEAUJXN TRIA1_HUMAN Decreases Expression [37]
NUAK family SNF1-like kinase 1 (NUAK1) OTLLHJJQ NUAK1_HUMAN Decreases Expression [37]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) OTYG179K PR15A_HUMAN Increases Expression [37]
Solute carrier organic anion transporter family member 2B1 (SLCO2B1) OTERJ4VQ SO2B1_HUMAN Decreases Expression [37]
Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 (GCNT3) OTQ9ALTR GCNT3_HUMAN Increases Expression [37]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Activity [37]
Alpha-enolase (ENO1) OTB1KWJS ENOA_HUMAN Increases Expression [37]
Bifunctional glutamate/proline--tRNA ligase (EPRS1) OTXK0FLB SYEP_HUMAN Increases Expression [37]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Increases Expression [37]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Increases Expression [37]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [37]
RNA-binding protein RO60 (RO60) OTLGM5A8 RO60_HUMAN Decreases Expression [37]
Retinoic acid receptor alpha (RARA) OT192V9V RARA_HUMAN Decreases Expression [37]
Histone H1.2 (H1-2) OT0AVI4M H12_HUMAN Decreases Expression [37]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Increases Expression [37]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Affects Activity [37]
Transcription factor E3 (TFE3) OTM99ZWH TFE3_HUMAN Increases Expression [37]
Retinoic acid receptor RXR-alpha (RXRA) OTP1TBDM RXRA_HUMAN Decreases Expression [37]
B-cell lymphoma 3 protein (BCL3) OT1M5B95 BCL3_HUMAN Decreases Expression [37]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Decreases Expression [37]
ETS domain-containing protein Elk-4 (ELK4) OTVSSEOE ELK4_HUMAN Increases Expression [37]
High affinity cationic amino acid transporter 1 (SLC7A1) OTR2ZVA8 CTR1_HUMAN Increases Expression [37]
Cystathionine gamma-lyase (CTH) OTC90LA0 CGL_HUMAN Increases Expression [37]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [37]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Affects Activity [37]
Glycine--tRNA ligase (GARS1) OT5B6R9Y GARS_HUMAN Increases Expression [37]
Isoleucine--tRNA ligase, cytoplasmic (IARS1) OT9WXH5N SYIC_HUMAN Increases Expression [37]
Eukaryotic translation initiation factor 1 (EIF1) OTB4GZ0V EIF1_HUMAN Increases Expression [37]
Sodium- and chloride-dependent glycine transporter 1 (SLC6A9) OTHRUON2 SC6A9_HUMAN Increases Expression [37]
Glutamate--cysteine ligase regulatory subunit (GCLM) OT6CP234 GSH0_HUMAN Increases Expression [37]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Increases Expression [37]
Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1) OTYHXLWZ BCAT1_HUMAN Decreases Expression [37]
Serine/threonine-protein kinase SIK1 (SIK1) OT6FCHME SIK1_HUMAN Increases Expression [37]
Large neutral amino acids transporter small subunit 1 (SLC7A5) OT2WPVXD LAT1_HUMAN Increases Expression [37]
1,4-alpha-glucan-branching enzyme (GBE1) OTK2N05B GLGB_HUMAN Increases Expression [37]
Adenylate cyclase type 1 (ADCY1) OTSLLFZO ADCY1_HUMAN Decreases Expression [37]
Ras-related protein Rab-31 (RAB31) OTMLXQZ0 RAB31_HUMAN Decreases Expression [37]
Enhancer of filamentation 1 (NEDD9) OTGCFN4M CASL_HUMAN Decreases Expression [37]
Probable E3 ubiquitin-protein ligase HERC3 (HERC3) OTWMKYD9 HERC3_HUMAN Increases Expression [37]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Affects Activity [37]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Decreases Expression [37]
Neuronal regeneration-related protein (NREP) OT2AZPKK NREP_HUMAN Decreases Expression [37]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Affects Activity [37]
Dual specificity protein phosphatase 5 (DUSP5) OTH96RA7 DUS5_HUMAN Increases Expression [37]
Glycerol-3-phosphate acyltransferase 3 (GPAT3) OTJUGPK0 GPAT3_HUMAN Increases Expression [37]
Quinone oxidoreductase PIG3 (TP53I3) OTSCM68G QORX_HUMAN Decreases Expression [37]
Extracellular sulfatase Sulf-2 (SULF2) OTIXMUVL SULF2_HUMAN Decreases Expression [37]
Probable ATP-dependent RNA helicase DHX37 (DHX37) OTM1A5KP DHX37_HUMAN Increases Expression [37]
SH3 domain and tetratricopeptide repeat-containing protein 1 (SH3TC1) OT0HYZIU S3TC1_HUMAN Increases Expression [37]
Sortilin-related receptor (SORL1) OTQ8FFNS SORL_HUMAN Decreases Expression [37]
KICSTOR complex protein ITFG2 (ITFG2) OT0NLZ8I ITFG2_HUMAN Increases Expression [37]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1) OT2363Z9 T53I1_HUMAN Decreases Expression [37]
Protein FAM89A (FAM89A) OTNASAXT FA89A_HUMAN Increases Expression [37]
Spermatid perinuclear RNA-binding protein (STRBP) OTU7XLZL STRBP_HUMAN Increases Expression [37]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [37]
Protein orai-3 (ORAI3) OTUP3OH3 ORAI3_HUMAN Decreases Expression [37]
Ferroptosis suppressor protein 1 (AIFM2) OT57XWXO FSP1_HUMAN Increases Expression [37]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Increases Expression [37]
Ankyrin repeat family A protein 2 (ANKRA2) OTLSLV5A ANRA2_HUMAN Increases Expression [37]
Gephyrin (GPHN) OTAKK1SV GEPH_HUMAN Increases Expression [37]
Ectonucleoside triphosphate diphosphohydrolase 7 (ENTPD7) OT3QER33 ENTP7_HUMAN Decreases Expression [37]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Decreases Expression [37]
Leucine--tRNA ligase, cytoplasmic (LARS1) OT4557NF SYLC_HUMAN Increases Expression [37]
Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (ARFGEF2) OTM3CQZT BIG2_HUMAN Increases Expression [37]
Bifunctional epoxide hydrolase 2 (EPHX2) OTPTRCNW HYES_HUMAN Affects Expression [48]
Cytochrome P450 2J2 (CYP2J2) OTJBTEH8 CP2J2_HUMAN Affects Expression [48]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Increases Expression [49]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [50]
Apolipoprotein A-I (APOA1) OT5THARI APOA1_HUMAN Decreases Expression [51]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Decreases Expression [52]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Expression [53]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Activity [54]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Decreases Expression [52]
Matrilysin (MMP7) OTVT3SEJ MMP7_HUMAN Decreases Expression [52]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [55]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Increases Expression [56]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Expression [52]
Fatty acid-binding protein, adipocyte (FABP4) OT3DKFOU FABP4_HUMAN Increases Expression [57]
Polyunsaturated fatty acid lipoxygenase ALOX12 (ALOX12) OTFL5KR5 LOX12_HUMAN Increases Expression [57]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Affects Localization [52]
Cytochrome P450 7A1 (CYP7A1) OT8Z5KLD CP7A1_HUMAN Decreases Expression [58]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Decreases Expression [50]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Decreases Expression [52]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [59]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Increases Expression [49]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Expression [56]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Decreases Expression [56]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A) OTI862QH CPT1A_HUMAN Increases Expression [60]
5'-AMP-activated protein kinase subunit gamma-1 (PRKAG1) OTW00PRY AAKG1_HUMAN Increases Expression [52]
Oxysterols receptor LXR-beta (NR1H2) OT4APA60 NR1H2_HUMAN Increases Expression [49]
Caveolin-1 (CAV1) OTEZUR1L CAV1_HUMAN Increases Expression [61]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Increases Expression [49]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [50]
Platelet-activating factor acetylhydrolase (PLA2G7) OT6H6AMO PAFA_HUMAN Decreases Activity [62]
Oxysterols receptor LXR-alpha (NR1H3) OT54YZ9I NR1H3_HUMAN Increases Expression [49]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [50]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Increases Expression [63]
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Increases Expression [59]
Bcl-2-related protein A1 (BCL2A1) OTWRYSNA B2LA1_HUMAN Decreases Expression [50]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [54]
Proprotein convertase subtilisin/kexin type 9 (PCSK9) OTI0DU9Y PCSK9_HUMAN Increases Expression [53]
Scavenger receptor class B member 1 (SCARB1) OTAE1UA1 SCRB1_HUMAN Increases Expression [64]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Increases Expression [65]
Tribbles homolog 3 (TRIB3) OTG5OS7X TRIB3_HUMAN Decreases Expression [66]
Semaphorin-6B (SEMA6B) OT3VVVUO SEM6B_HUMAN Decreases Expression [67]
Fibroblast growth factor 21 (FGF21) OT3RXVRD FGF21_HUMAN Increases Expression [68]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) OT1OG4QZ AAKB1_HUMAN Increases Phosphorylation [52]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) OT7TNF0L AAPK1_HUMAN Decreases Response To Substance [52]
HLA class I histocompatibility antigen, A alpha chain (HLA-A) OTAH14LU HLAA_HUMAN Affects Response To Substance [69]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Affects Response To Substance [70]
------------------------------------------------------------------------------------
⏷ Show the Full List of 240 DOT(s)

References

1 ClinicalTrials.gov (NCT02452255) Fenofibrate and Propranolol in Burn Patients
2 Propranolol FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7596).
4 Fenofibrate FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7186).
6 beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFB and AP-1. Cancer Biol Ther. 2010 Jul 1;10(1):19-29.
7 Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
8 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
9 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
10 Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
11 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
12 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
13 The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992 Dec;32(12):1099-104.
14 Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001 Oct;52(4):349-55.
15 Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis. Microb Cell Fact. 2015 Jun 12;14:82.
16 acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
17 Comparative study of the oxidation of propranolol enantiomers in hepatic and small intestinal microsomes from cynomolgus and marmoset monkeys. Chem Biol Interact. 2010 Jan 5;183(1):67-78. doi: 10.1016/j.cbi.2009.10.007.
18 Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions?. Biochem Pharmacol. 2004 Aug 15;68(4):783-90. doi: 10.1016/j.bcp.2004.05.006.
19 Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
20 Additional gene variants reduce effectiveness of beta-blockers in the LQT1 form of long QT syndrome. J Cardiovasc Electrophysiol. 2004 Feb;15(2):190-9. doi: 10.1046/j.1540-8167.2004.03212.x.
21 Propranolol inhibits proliferation and induces apoptosis of hemangioma-derived endothelial cells via Akt pathway by down-regulating Ang-2 expression. Chem Biol Interact. 2020 Jan 25;316:108925. doi: 10.1016/j.cbi.2019.108925. Epub 2019 Dec 12.
22 Development of a common carp (Cyprinus carpio) pregnane X receptor (cPXR) transactivation reporter assay and its activation by azole fungicides and pharmaceutical chemicals. Toxicol In Vitro. 2017 Jun;41:114-122. doi: 10.1016/j.tiv.2017.02.023. Epub 2017 Mar 1.
23 Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension. Am J Cardiol. 1975 Oct 31;36(5):716-21. doi: 10.1016/0002-9149(75)90174-5.
24 Labetalol (AH5158), a competitive alpha- and beta-receptor blocking drug, in the management of hypertension. Aust N Z J Med. 1976 Aug;6(3 Suppl):83-8. doi: 10.1111/j.1445-5994.1976.tb03341.x.
25 Beta-adrenergic contribution to glucagon-induced glucose production and insulin secretion in uremia. Am J Physiol. 1986 Sep;251(3 Pt 1):E322-7. doi: 10.1152/ajpendo.1986.251.3.E322.
26 Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer. 2004 Dec 16;4:93. doi: 10.1186/1471-2407-4-93.
27 Adrenergic modulation of cardiac development in the rat: effects of prenatal exposure to propranolol via continuous maternal infusion. J Dev Physiol. 1990 May;13(5):243-9.
28 Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation. 1998 Oct 27;98(17):1783-9. doi: 10.1161/01.cir.98.17.1783.
29 Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway. Chem Biol Interact. 2018 Oct 1;294:28-33. doi: 10.1016/j.cbi.2018.08.018. Epub 2018 Aug 18.
30 Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
31 Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell. Pancreas. 2009 Jan;38(1):94-100. doi: 10.1097/MPA.0b013e318184f50c.
32 An effector domain mutant of Arf6 implicates phospholipase D in endosomal membrane recycling. Mol Biol Cell. 2006 Jan;17(1):327-35. doi: 10.1091/mbc.e05-06-0523. Epub 2005 Nov 9.
33 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
34 Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology. 2006 Nov;44(5):1158-70.
35 Linalool is a PPARalpha ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110.
36 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
37 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
38 Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
39 Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
40 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
41 The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol Pol. 2005 Jun;62(6):526-30.
42 In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer. 2006 Mar 28;5:13.
43 Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur J Pharmacol. 2007 Oct 1;571(2-3):97-105.
44 Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. Eur J Pharmacol. 2008 Apr 28;584(2-3):213-21.
45 Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
46 Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism. 2011 Apr;60(4):513-22.
47 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
48 Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner. Toxicol Appl Pharmacol. 2018 Sep 15;355:156-163.
49 On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 2009 Aug;205(2):413-9. doi: 10.1016/j.atherosclerosis.2009.01.008. Epub 2009 Jan 19.
50 Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis. Leukemia. 2010 Aug;24(8):1476-86. doi: 10.1038/leu.2010.117. Epub 2010 Jun 3.
51 Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994 Dec 9;269(49):31012-8.
52 AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-B pathway. Environ Toxicol. 2016 Jul;31(7):866-76. doi: 10.1002/tox.22097. Epub 2014 Dec 24.
53 Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study. Atherosclerosis. 2011 Jul;217(1):165-70. doi: 10.1016/j.atherosclerosis.2011.02.012. Epub 2011 Feb 22.
54 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
55 Fenofibrate induces apoptotic injury in cultured human hepatocytes by inhibiting phosphorylation of Akt. Apoptosis. 2005 Mar;10(2):349-58. doi: 10.1007/s10495-005-0809-3.
56 Fenofibrate induced PPAR alpha expression was attenuated by oestrogen receptor alpha overexpression in Hep3B cells. Environ Toxicol. 2018 Feb;33(2):234-247. doi: 10.1002/tox.22511. Epub 2017 Nov 14.
57 Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
58 Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol. 2004 Feb;59(12):855-61. doi: 10.1007/s00228-003-0704-1. Epub 2003 Dec 18.
59 Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care. 2006 Feb;29(2):195-201. doi: 10.2337/diacare.29.02.06.dc05-1418.
60 Immunoselection and characterization of a human genomic PPAR binding fragment located within POTE genes. Biochimie. 2007 Mar;89(3):329-36. doi: 10.1016/j.biochi.2006.09.017. Epub 2006 Oct 18.
61 Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J Lipid Res. 2004 Nov;45(11):2015-24. doi: 10.1194/jlr.M400049-JLR200. Epub 2004 Aug 16.
62 The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis. 2007 Aug;193(2):428-37. doi: 10.1016/j.atherosclerosis.2006.07.010. Epub 2006 Sep 5.
63 Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. Hepatology. 2009 Sep;50(3):880-92. doi: 10.1002/hep.23049.
64 Aspirin regulates expression and function of scavenger receptor-BI in macrophages: studies in primary human macrophages and in mice. FASEB J. 2006 Jul;20(9):1328-35. doi: 10.1096/fj.05-5368com.
65 Fenofibrate inhibits hypoxia-inducible factor-1 alpha and carbonic anhydrase expression through activation of AMP-activated protein kinase/HO-1/Sirt1 pathway in glioblastoma cells. Environ Toxicol. 2021 Dec;36(12):2551-2561. doi: 10.1002/tox.23369. Epub 2021 Sep 14.
66 PML-RAR interaction with TRIB3 impedes PPAR/RXR function and triggers dyslipidemia in acute promyelocytic leukemia. Theranostics. 2020 Aug 15;10(22):10326-10340. doi: 10.7150/thno.45924. eCollection 2020.
67 Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells. Int J Oncol. 2006 Apr;28(4):977-84.
68 Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes. 2012 Apr;61(4):797-806. doi: 10.2337/db11-0846. Epub 2012 Feb 14.
69 Association of Liver Injury From Specific Drugs, or Groups of?Drugs, With Polymorphisms in HLA and Other Genes in a?Genome-Wide Association Study. Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30.
70 Interleukin-6 -174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients. Blood Coagul Fibrinolysis. 2006 Jan;17(1):35-8. doi: 10.1097/01.mbc.0000198052.65505.00.